On the evening of May 10 (Vietnam time), in the capital Moscow (Russia), under the witness of Russian President Vladimir Putin and General Secretary To Lam, Vietnam Vaccination Company (VNVC) and the Russian Direct Investment Fund (RDIF) signed a strategic cooperation agreement in the field of scientific research and technology transfer for vaccine and biological drug production.
The document signed between Russian direct investment fund (RDIF) and VNVC Vaccine Company was awarded in the witness of the two heads of the two countries of Vietnam and Russia during the official visit to the Russian Federation of General Secretary To Lam from May 8 to 11, on the occasion of the 80th anniversary of the victory day in the great national war and 75 years of establishing Vietnam -Russian diplomatic relations.
According to the cooperation agreement between RDIF and VNVC, the two sides will discuss to establish a platform for in-depth cooperation on high technology in the field of Biomedicine, focusing on research, investment, technology transfer and trade of biological drugs and high-tech vaccines.
In particular, VNVC's top expectation is to soon bring to Vietnam a potential cancer treatment vaccine using the leading modern mRNA technology that Russia has recently announced.
In addition to this important cooperation document, VNVC also signed a cooperation agreement with the National Center for Epidemiology and Bi Bi Biology Gamaleya on cooperation in scientific research and development of biotechnology. The research topics will be deployed in the near future.
Also within the framework of the cooperation announced between the two official representatives in the health sector of the two countries, VNVC also signed with Russian Pharmaceutical Group Binnopharm, one of the largest pharmaceutical manufacturers in Russia.
Immediately after the signing, VNVC will start scientific exchanges with scientists from many Russian research institutes and high-end hospitals to receive technology transfer for research, testing and vaccine production using mRNA technology.
Previously, in December 2024, the National Center for Medical Research on X-rays under the Russian Ministry of Health announced that the country is researching and developing a potential lung cancer treatment vaccine, produced using advanced mRNA technology.
According to the cooperation agreement between RDIF and VNVC, potential Russian mRNA technology vaccines will be soon imported by VNVC right from the early clinical trial so that patients have the opportunity to access more modern solutions that are at the world's leading with a very high success rate after treatment.
In addition, the implementation of clinical trials on biological drugs and advanced technology vaccines in Vietnam by Russia also helps the registration of licenses and product commercialization to be more convenient and faster as soon as good results are achieved.
This important cooperation between VNVC and the world's leading major partner continues to affirm the remarkable growth of Vietnamese healthcare on the world healthcare map, contributing to enhancing the country's position in the new era.
In the immediate and specific, this cooperation is considered a concrete action to realize the policy from Resolution 57 of the Politburo, signed and issued by General Secretary To Lam on December 22, 2024 on breakthroughs in the development of science, technology, innovation and national digital transformation.
Scientific cooperation activities and technology transfer between Vietnam and Russia are expected to open up great development opportunities for the fields of scientific research, production of high-tech vaccines and advanced cancer treatments for Vietnam.
Mr. Kirill Dmitriev, Special Representative of the Russian President for Foreign Economic and Investment, General Director of the Russian Direct Investment Fund (RDIF), said: Russia and Vietnam have many conditions for investment cooperation and technology transfer, especially in the fields of medicine and health care.
During the Covid-19 pandemic, Vietnam was one of the countries that approved the use of Russia's Sputnik V against Covid-19 vaccine. The cooperation framework we announce today will play an important role in enhancing scientific exchanges and technology transfer between the two countries to develop pioneering health care products.
Appreciating the cooperative relationship with prestigious Russian agencies, Mr. Ngo Chi Dung, Chairman of the Board of Directors and CEO of VNVC Vaccine Company affirmed that this is an important milestone, opening up opportunities for Vietnam to access and test vaccines on the most advanced mRNA technology that Russia is promoting research and development.
The two sides will discuss to open up opportunities for Vietnam to soon access potential Russian mRNA technology cancer vaccines, not only clinical research and product commercialization but also production at the VNVC vaccine and food factory in Long An.
In the context of Vietnam recording hundreds of thousands of new cases and deaths from cancer each year, this important cooperation agreement will open up new opportunities for cancer treatment with the first vaccine in the country, contributing to saving costs and improving the quality of life for people, Mr. Ngo Chi Dung emphasized.
